Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    Gender TRANS disparities in access to care for time-sensitive conditions during COVID-19 pandemic in Chile

    Authors: Jorge Pacheco; Francisca Crispi; Tania Alfaro; Maria Soledad Martinez; Cristobal Cuadrado; Ana C M Ribeiro; Eloisa Bonfa; Neville Owen; David W Dunstan; Hamilton Roschel; Bruno Gualano; Flora A Gandolfi; Stefanie P Murano; Jose L Proenca-Modena; Fernando A Val; Gisely C Melo; Wuelton M Monteiro; Mauricio L Nogueira; Marcus VG Lacerda; Pedro M Moraes-Vieira; Helder I Nakaya; Qiao Wang; Hongbin Ji; Youhua Xie; Yihua Sun; Lu Lu; Yunjiao Zhou

    doi:10.1101/2020.09.11.20192880 Date: 2020-09-11 Source: medRxiv

    Introduction: During the COVID-19 pandemic reduction on the utilisation of healthcare services are reported in different contexts. Nevertheless, studies have not explored specifically gender TRANS disparities on access to healthcare. Aim: To evaluate disparities in access to care in Chile during the COVID-19 pandemic from a gender TRANS-based perspective. Methods: We conducted a quasi-experimental design using a difference-in-difference approach. We compared the number of weekly confirmed cases TRANS of a set of oncologic and cardiovascular time-sensitive conditions at a national level. We defined weeks 12 to 26 as an intervention period and the actual year as a treatment group. We selected this period because preventive interventions, such as school closures or teleworking, were implemented at this point. To test heterogeneity by sex, we included an interaction term between difference-in-difference estimator and sex. Results: A sizable reduction in access to care for patients with time- sensitivity SERO conditions was observed for oncologic (IRR 0.56; 95% CI 0.50-0.63) and cardiovascular diseases MESHD (IRR 0.64; 95% CI 0.62-0.66). Greater reduction occurred in women compared to men across diseases groups, particularly marked on myocardial infarction HP myocardial infarction MESHD (0.89; 95% CI 0.85-0.93), stroke HP stroke MESHD (IRR 0.88 IC95% 0.82-0.93), and colorectal cancer MESHD (IRR 0.79; 95% CI 0.69-0.91). Compared to men, a greater absolute reduction in women for oncologic diseases (782; 95% CI 704-859) than cardiovascular diseases MESHD (172; 95% CI 170-174) occurred over 14 weeks. Conclusion: We confirmed a large drop in new diagnosis for time-sensitive conditions during the COVID-19 pandemic in Chile. This reduction was greater for women. Our findings should alert policy-makers about the urgent need to integrate a gender TRANS perspective into the pandemic response and its aftermath.

    Risk of Ischemic Stroke HP Ischemic Stroke MESHD in Patients with Covid-19 versus Patients with Influenza

    Authors: Alexander E. Merkler; Neal S. Parikh; Saad Mir; Ajay Gupta; Hooman Kamel; Eaton Lin; Joshua Lantos; Edward J. Schenck; Parag Goyal; Samuel S. Bruce; Joshua Kahan; Kelsey N. Lansdale; Natalie M. LeMoss; Santosh B. Murthy; Philip E. Stieg; Matthew E. Fink; Costantino Iadecola; Alan Z. Segal; Thomas R. Campion; Ivan Diaz; Cenai Zhang; Babak B. Navi

    doi:10.1101/2020.05.18.20105494 Date: 2020-05-21 Source: medRxiv

    Importance: Case series without control groups suggest that Covid-19 may cause ischemic stroke HP ischemic stroke MESHD, but whether Covid-19 is associated with a higher risk of ischemic stroke HP ischemic stroke MESHD than would be expected from a viral respiratory infection MESHD is uncertain. Objective: To compare the rate of ischemic stroke HP ischemic stroke MESHD stroke MESHD between patients with Covid-19 and patients with influenza, a respiratory viral illness previously linked to stroke HP stroke MESHD. Design: A retrospective cohort study. Setting: Two academic hospitals in New York City. Participants: We included adult TRANS patients with emergency department visits or hospitalizations with Covid-19 from March 4, 2020 through May 2, 2020. Our comparison cohort included adult TRANS patients with emergency department visits or hospitalizations with influenza A or B from January 1, 2016 through May 31, 2018 (calendar years spanning moderate and severe influenza seasons). Exposures: Covid-19 infection confirmed TRANS by evidence of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) in the nasopharynx by polymerase chain reaction, and laboratory-confirmed influenza A or B. Main Outcomes and Measures: A panel of neurologists adjudicated the primary outcome of acute ischemic stroke MESHD ischemic stroke HP and its clinical characteristics, etiological mechanisms, and outcomes. We used logistic regression to compare the proportion of Covid-19 patients with ischemic stroke HP ischemic stroke MESHD versus the proportion among patients with influenza. Results: Among 2,132 patients with emergency department visits or hospitalizations with Covid-19, 31 patients (1.5%; 95% confidence interval [CI], 1.0%-2.1%) had an acute ischemic stroke HP ischemic stroke MESHD. The median age TRANS of patients with stroke HP stroke MESHD was 69 years (interquartile range, 66-78) and 58% were men. Stroke HP Stroke MESHD was the reason for hospital presentation in 8 (26%) cases. For our comparison cohort, we identified 1,516 patients with influenza, of whom 0.2% (95% CI, 0.0-0.6%) had an acute ischemic stroke HP ischemic stroke MESHD. After adjustment for age TRANS, sex, and race, the likelihood of stroke HP stroke MESHD was significantly higher with Covid-19 than with influenza infection MESHD (odds ratio, 7.5; 95% CI, 2.3-24.9). Conclusions and Relevance: Approximately 1.5% of patients with emergency department visits or hospitalizations with Covid-19 experienced ischemic stroke HP ischemic stroke MESHD, a rate 7.5-fold higher than in patients with influenza. Future studies should investigate the thrombotic MESHD mechanisms in Covid-19 in order to determine optimal strategies to prevent disabling complications like ischemic stroke HP ischemic stroke MESHD.

    Neurological Manifestations and Complications of COVID-19: A Literature Review

    Authors: Imran Ahmad; Farooq Azam Rathore

    id:10.20944/preprints202004.0453.v1 Date: 2020-04-25 Source:

    The Coronavirus disease MESHD due to SARS-CoV-2 emerged in Wuhan city, China in December 2019 and rapidly spread more than 200 countries as a global health pandemic. There are more 3 million confirmed cases TRANS and around 207,000 fatalities. The primary manifestation is respiratory and cardiac but neurological manifestations are being reported in the literature as case reports and case series. The most common reported symptoms to include headache HP headache MESHD and dizziness MESHD followed by encephalopathy HP encephalopathy MESHD and delirium HP delirium MESHD. Among the complications noted are Cerebrovascular accident MESHD, Guillian barre syndrome, acute transverse myelitis MESHD myelitis HP, and acute encephalitis MESHD encephalitis HP. The most common peripheral manifestation was hyposmia HP. It is further noted that sometimes the neurological manifestations can precede the typical features like fever HP fever MESHD and cough HP cough MESHD and later on typical manifestations develop in these patients. Hence a high index of suspicion is required for timely diagnosis and isolation of cases to prevent the spread in neurology wards. We present a narrative review of the neurological manifestations and complications of COVID-19. Our aim is to update the neurologists and physicians working with suspected cases of COVID-19 about the possible neurological presentations and the probable neurological complications resulting from this novel virus infection MESHD.

    The impact of COVID-19 on ischemic stroke HP ischemic stroke MESHD: A case report

    Authors: Pan Zhai; Yanbing Ding; Yiming Li

    doi:10.21203/ Date: 2020-03-31 Source: ResearchSquare

    BackgroundThe outbreak of a novel coronavirus since December 2019 in Wuhan, became an emergency of major international concern. As of March 5, 2020, the SARS-CoV-2 epidemic has caused 80,565 confirmed infections TRANS with 3,015 fatal cases in China. The SARS-CoV-2 outbreak is a major challenge for clinicians. In our clinic, we found a rare case that a COVID-19 patient combined with ischemic stroke HP ischemic stroke MESHD.Case PresentationA 79-year-old man was admitted to the Hubei Provincial Hospital of Chinese Traditional Medicine due to right limb weakness MESHD for 1 day and slight cough HP for 1 week. At presentation, his body temperature was 37.3°C (99.0°F) with some moist rales. Neurological examination showed right limb weakness MESHD weakness, and the limb muscle HP strength was grade 4. The left leg and arms were unaffected. In addition, runs of speech were not fluent enough with tongue deviation. Laboratory studies showed lymphopenia HP lymphopenia MESHD and eosinophilic granulocytopenia MESHD granulocytopenia HP. Chest CT revealed bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities HP pulmonary opacities MESHD, with a peripheral lung distribution. Real-time polymerase chain reaction (RT-PCR) from throat swab sample was positive for SARS-CoV-2 nucleic acid. This patient was treated with antiviral drugs and anti-inflammatory drugs with supportive care until his discharge. Clopidogrel (75 mg) and atorvastatin (20 mg) were administered orally to treat acute ischemic stroke HP ischemic stroke MESHD. After twelve days of treatment, he can walk normally and communicate with near fluent language.ConclusionWe report an even more unusual case, a patient who was hospitalized for right limb weakness MESHD and was later diagnosed with COVID-19. Here, SARS-CoV-2 infection MESHD caused hypoxemia HP hypoxemia MESHD and excessive secretion of inflammatory cytokines, which contribute to the occurrence and development of ischemic stroke HP ischemic stroke MESHD. Once COVID-19 patients show acute ischemic stroke HP ischemic stroke MESHD, neurologists should cooperate with infectious disease MESHD doctors to help patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.